Inflammation, oxidative stress and metabolic syndrome: Dietary modulation

Current Vascular Pharmacology

Volumn 11, Issue 6, 2013, Pages 906-919

  Fernández García, José C ^a,b   Cardona, Fernando ^a,b   Tinahones, Francisco J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Dietary modulation; Inflammation; Mediterranean diet; Metabolic syndrome; Oxidative stress; Polyphenols; Resveratrol

Indexed keywords

ADALIMUMAB; ADIPONECTIN; ALPHA TOCOPHEROL; ASCORBIC ACID; CAPSAICIN; CURCUMIN; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; ISOFLAVONE; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OLIVE OIL; POLYPHENOL DERIVATIVE; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

CACAO; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIET THERAPY; DYSLIPIDEMIA; ELEVATED BLOOD PRESSURE; GINGER; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; INFLAMMATION; MEDITERRANEAN DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TEA; TOMATO;

ANIMALS; ANTIOXIDANTS; DIET; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; METABOLIC SYNDROME X; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84893469766     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113116660175     Document Type: Review

References (198)

1. Finucane MM, Stevens GA, Cowan MJ, et al. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in bodymass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011; 377: 557-67.
2. Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-60.
3. th January 2012).
4. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352: 1138-45.
5. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
6. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-9.
7. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol 2010; 25: 375-84.
8. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-61.
9. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-9.
10. Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 2011; 15: 1911-26.
11. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag 2006; 2: 145-52.
12. Kim MS, Lee MS, Kown DY. Inflammation-mediated obesity and insulin resistance as targets for nutraceuticals. Ann N Y Acad Sci 2011; 1229: 140-6.
13. Garcia-Bailo B, El-Sohemy A, Haddad PS, et al. Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress. Biologics 2011; 5: 7-19.
14. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
15. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
16. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
18. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56.
19. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
20. Prins JB. Adipose tissue as an endocrine organ. Best Pract Res Clin Endocrinol Metab 2002; 16: 639-51.
21. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
22. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
23. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-β in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15.
24. Bulló M, García-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003; 11: 525-31.
25. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996; 271: 665-8.
26. Araújo EP, De Souza CT, Ueno M, et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 2007; 148: 5991-7.
27. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 2010; 1193: 153-9.
28. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414-7.
29. Barbarroja N, Lopez-Pedrera R, Mayas MD, et al. The obese healthy paradox: is inflammation the answer? Biochem J 2010; 430: 141-9.
30. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278-301.
31. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-37.
32. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-6.
33. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
34. Karin M. The IkappaB kinase-a bridge between inflammation and cancer. Cell Res 2008; 18: 334-42.
35. Gonzalez F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1508-12.
36. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002; 51: 1319-36.
37. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867-74.
38. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-64.
39. Tanti JF, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 2009 9: 753-62.
40. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-8.
41. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-7.
42. Werner ED, Lee J, Hansen L, Yuan M, Shoelson SE. Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem 2004; 279: 35298-305.
43. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
44. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-505.
45. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 7265-70.
46. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110: 1564-71.
47. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006; 30: 400-18.
48. Fridlyand LE, Philipson LH. Oxidative reactive species in cell injury: Mechanisms in diabetes mellitus and therapeutic approaches. Ann N Y Acad Sci 2005; 1066: 136-51.
49. Wood ZA, Schröder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 2003; 28: 32-40.
50. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
51. Ozata M, Mergen M, Oktenli C. Increased oxidative stress and hypozincemia in male obesity. Clin Biochem 2002; 35: 627-31.
52. Olusi SO. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotective enzymes in humans. Int J Obes Relat Metab Disord 2002; 26: 1159-64.
53. Cardona F, Túnez I, Tasset I, Montilla P, Collantes E, Tinahones FJ. Fat overload aggravates oxidative stress in patients with the metabolic syndrome. Eur J Clin Invest 2008; 38: 510-5.
54. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994; 106: 83-97.
55. Cardona F, Tinahones FJ. Relación de la hipertrigliceridemia postprandial con la resistencia a la insulina en pacientes con síndrome metabólico. Endocrinol Nutr 2006; 53: 345-52.
56. Prónai L, Hiramatsu K, Saigusa Y, Nakazawa H. Low superoxide scavenging activity associated with enhanced superoxide generation by monocytes from male hypertriglyceridemia with and without diabetes. Atherosclerosis 1991; 90: 39-47.
57. Tinahones FJ, Muri-Pierri M, Garrido-Sánchez L, et al. Oxidative stress in severely obese persons is greater in those with insulin resistance. Obesity (Silver Spring) 2009; 17: 240-6.
58. Efe H, Deger O, Kirci D. Decreased neutrophil antioxidative enzyme activities and increased lipid peroxidation in hyperlipoproteinemic human subjects. Clin Chim Acta 1999; 279: 155-65.
59. Cardona F, Túnez I, Tasset I. Circulating antioxidant defences are decreased in healthy people after a high-fat meal. Br J Nutr 2008; 100: 312-6.
60. de Koning EJ, Rabelink TJ. Endothelial function in the postprandial state. Atherosclerosis 2002; 3: 11-6.
61. Cardona F, Túnez I, Tasset I, Murri M, Tinahones FJ. Similar increase in oxidative stress after fat overload in persons with baseline hypertriglyceridemia with or without the metabolic syndrome. Clin Biochem 2008; 41: 701-5.
62. Ursini F, Sevanian A. Postprandial oxidative stress. Biol Chem 2002; 383: 599-605.
63. Abete I, Goyenechea E, Zulet MA, Martínez JA. Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr Metab Cardiovasc Dis 2011; 21 (Suppl 2): B1-15.
64. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase Ctheta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-4.
65. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003; 14: 15-9.
66. Calder PC, Albers R, Antoine JM, et al. Inflammatory disease processes and interactions with nutrition. Br J Nutr 2009; 101 Suppl 1: S1-S45.
67. Ness AR, Powless JW, Khaw KT. Vitamin C and cardiovascular disease: a systematic review. J Cardiovasc Risk 1996; 3: 513-21.
68. Mah E, Matos MD, Kawiecki D, et al. Vitamin C status is related to proinflammatory responses and impaired vascular endothelial function in healthy, college-aged lean and obese men. J Am Diet Assoc 2011; 111: 737-43.
69. Barker T, Leonard SW, Trawick RH, et al. Modulation of inflammation by vitamin E and C supplementation prior to anterior cruciate ligament surgery. Free Radic Biol Med 2009; 46: 599-606.
70. Babar M, Abdel-Latif MM, Ravi N, et al. Pilot translational study of dietary vitamin C supplementation in Barrett's esophagus. Dis Esophagu 2010; 23: 271-6.
71. Cahill L, Corey PN, El-Sohemy A. Vitamin C deficiency in a population of young Canadian adults. Am J Epidemiol 2009; 170: 464-71.
72. Wannamethee SG, Lowe GD, Rumley A, Bruckdorfer KR, Whincup PH. Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. Am J Clin Nutr 2006; 83: 567-74.
73. Helmersson J, Arnlöv J, Larsson A, Basu S. Low dietary intake of beta-carotene, alpha-tocopherol and ascorbic acid is associated with increased inflammatory and oxidative stress status in a Swedish cohort. Br J Nutr 2009; 101: 1775-82.
74. Harding AH, Warejan NJ, Bingham SA, et al. Plasma vitamin C level, fruit and vegetable consumption, and the risk of new-onset type 2 diabetes mellitus: the European prospective investigation of cancer-Norfolk prospective study. Arch Intern Med 2008; 168: 1493-9.
75. Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation in diabetes mellitus. Ann Nutr Metab 1995; 39: 217-23.
76. Paolisso G, Balbi V, Volpe C, et al. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll Nutr 1995; 14: 387-92.
77. Lu Q, Björkhem I, Wretlind B, Diczfalusy U, Henriksson P, Freyschuss A. Effect of ascorbic acid on microcirculation in patients with type II diabetes: a randomized placebo-controlled cross-over study. Clin Sci (Lond) 2005; 108: 507-13.
78. Tousoulis D, Antoniades C, Vasiliadou C, et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart 2007; 93: 244-6.
79. Chen H, Karne RJ, Hall G, et al. High-dose oral vitamin C partially replenishes vitamin C levels in patients with type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol 2006; 290: H137-45.
80. Traber MG, Packer L. Vitamin E: beyond antioxidant function. Am J Clin Nutr 1995; 62: 1501S-1509S.
81. Jiang Q, Christen S, Shigenaga MK, Ames BN. Gammatocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 2001; 74: 714-22.
82. Facchini FS, Humphreys MH, DoNascimento CA, Abbasi F, Reaven GM. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am J Clin Nutr 2000; 72: 776-9.
83. Salonen JT, Nyyssönen K, Tuomainen TP, et al. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. BMJ 1995; 311: 1124-7.
84. Palmieri VO, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 2006; 136: 3022-6.
85. Violi F, Cangemi R, Sabatino G, Pignatelli P. Vitamin E for the treatment of cardiovascular disease: is there a future? Ann N Y Acad Sci 2004; 1031: 292-304.
86. Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation 2000; 102: 191-6.
87. Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med 2000; 29: 790-2.
88. Devaraj S, Tang R, Adams-Huet B, et al. Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr 2007; 86: 1392-8.
89. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
90. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-55.
91. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154-60.
92. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-8.
93. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
94. Mason RS, Sequeira VB, Gordon-Thomson C. Vitamin D: the light side of sunshine. Eur J Clin Nutr 2011; 65: 986-93.
95. Osei K. 25-OH vitamin D: is it the universal panacea for metabolic syndrome and type 2 diabetes? J Clin Endocrinol Metab 2010; 95: 4220-2.
96. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 1985; 76: 370-3.
97. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000 72: 690-3.
98. Van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
99. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R, Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83: 754-9.
100. 3 on IL-10 expression in monocytes is short-term down-regulation. Biochim Biophys Acta 2010; 1803: 1276-86.
101. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammationlinked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011; 57: 63-9.
102. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
103. Moy FM, Bulgiba A. High prevalence of vitamin D insufficiency and its association with obesity and metabolic syndrome among Malay adults in Kuala Lumpur, Malaysia. BMC Public Health 2011; 11: 735.
104. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-5.
105. Kayaniyil S, Vieth R, Harris SB, Retnakaran R, et al. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab 2011; 96: 168-75.
106. Brenner DR, Arora P, Garcia-Bailo B, et al. Plasma vitamin D levels and risk of metabolic syndrome in Canadians. Clin Invest Med 2011; 34: E377.
107. Al-Daghri NM, Alkharfy KM, Al-Saleh Y, et al. Modest reversal of metabolic syndrome manifestations with vitamin D status correction: a 12-month prospective study. Metabolism 2002; 61: 661-6.
108. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 1931-42.
109. Kang JH, Kim CS, Han IS, Kawada T, Yu R. Capsaicin, a spicy component of hot peppers, modulates adipokine gene expression and protein release from obese-mouse adipose tissues and isolated adipocytes, and suppresses the inflammatory responses of adipose tissue macrophages. FEBS Lett 2007; 581: 4389-96.
110. Kang JH, Goto T, Han IS, Kawada T, Kim YM, Yu R. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity (Silver Spring) 2010; 18: 780-7.
111. Choi SE, Kim TH, Yi SA, et al. Capsaicin attenuates palmitateinduced expression of macrophage inflammatory protein 1 and interleukin 8 by increasing palmitate oxidation and reducing c-Jun activation in THP-1 (human acute monocytic leukemia cell) cells. Nutr Res 2011; 31: 468-78.
112. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010; 30: 173-99.
113. Kadnur SV, Goyal RK. Beneficial effects of Zingiber officinale Roscoe on fructose induced hyperlipidemia and hyperinsulinemia in rats. Indian J Exp Biol 2005; 43: 1161-4.
114. Okamoto M, Irii H, Tahara Y, et al. Synthesis of a new [6]-gingerol analogue and its protective effect with respect to the development of metabolic syndrome in mice fed a high-fat diet. J Med Chem 2011; 54: 6295-304.
115. Sekiya K, Ohtani A, Kusano S. Enhancement of insulin sensitivity in adipocytes by ginger. Biofactors 2004; 22: 153-6.
116. Woo HM, Kang JH, Kawada T, Yoo H, Sung MK, Yu R. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci 2007; 80: 926-31.
117. Carreau JP. Biosynthesis of lipoic acid via unsaturated fatty acids. Meth Enzymol 1979: 152-8.
118. Bast A, Haenen GR. Lipoic acid: a multifunctional antioxidant. Biofactors 2003; 17: 207-13.
119. Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-50.
120. Goríca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B. Lipoic acid-biological activity and therapeutic potential. Pharmacol Rep 2011; 63: 849-58.
121. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12: 1161-208.
122. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343-8.
123. Holmquist L, Stuchbury G, Berbaun K. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007; 113: 154-64.
124. Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr Rev 2008; 66: 646-57.
125. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999; 107: 421-30.
126. Ludwig DS. Clinical update: the low-glycaemic-index diet. Lancet. 2007; 369: 890-2.
127. Dhindsa S, Tripathy D, Mohanty P, et al. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappa-B in mononuclear cells. Metabolism 2004; 53: 330-4.
128. Dickinson S, Hancock DP, Petocz P, Ceriello A, Brand-Miller J. High-glycemic index carbohydrate increases nuclear factor-kappaB activation in mononuclear cells of young, lean healthy subjects. Am J Clin Nutr 2008; 87: 1188-93.
129. Botero D, Ebbeling CB, Blumberg JB, et al. Acute effects of dietary glycemic index on antioxidant capacity in a nutrientcontrolled feeding study. Obesity (Silver Spring) 2009; 17: 1664-70.
130. Kallio P, Kolehmainen M, Laaksonen DE, et al. Inflammation markers are modulated by responses to diets differing in postprandial insulin responses in individuals with the metabolic syndrome. Am J Clin Nutr 2008; 87: 1497-503.
131. Qi L, Hu FB. Dietary glycemic load, whole grains, and systemic inflammation in diabetes: the epidemiological evidence. Curr Opin Lipidol 2007; 18: 3-8.
132. Van Schothorst EM, Bunschoten A, Schrauwen P, Mensink RP, Keijer J. Effects of a high-fat, low versus high glycemic index diet: retardation of insulin resistance involves adipose tissue modulation. FASEB J 2009; 23: 1092-101.
133. Wang L, Folsom AR, Zheng ZJ, Pankow JS, Eckfeldt JH. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2003; 78: 91-8.
134. Kusunoki J, Katanani A, Moller DE. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. Endocrine 2006; 29: 91-100.
135. Aguilera CM, Ramírez-Tortosa MC, Mesa MD, Gil A. Protective effect of monounsaturated and polyunsaturated fatty acids on the development of cardiovascular disease. Nutr Hosp 2001; 16: 78-91.
136. Bradley RL, Fisher FF, Maratos-Flier E. Dietary fatty acids differentially regulate production of TNF-alpha and IL-10 by murine 3T3-L1 adipocytes. Obesity (Silver Spring) 2008; 16: 938-44.
137. Ajuwon KM, Spurlock ME. Palmitate activates the NF-+B transcription factor and induces IL-6 and TNF α expression in 3T3-L1 adipocytes. J Nutr 2005; 135: 1841-6.
138. Moreno JA, López-Miranda J, Pérez-Martínez P, et al. A monounsaturated fatty acid-rich diet reduces macrophage uptake of plasma oxidised low-density lipoprotein in healthy young men. Br J Nutr 2008; 100: 569-75.
139. Pérez-Martínez P, Moreno-Conde M, Cruz-Teno C, et al. Dietary fat differentially influences regulatory endothelial function during the postprandial state in patients with metabolic syndrome: From the LIPGENE study. Atherosclerosis 2010; 209: 533-38.
140. Jiménez-Gómez Y, Marín C, Pérez-Martínez P, et al. A low-fat, high-complex carbohydrate diet supplemented with long-chain (n-3) fatty acids alters the postprandial lipoprotein profile in patients with metabolic syndrome. J Nutr 2010; 140: 1595-601.
141. Perez-Martinez P, Garcia-Quintana JM, Yubero-Serrano EM, et al. Postprandial oxidative stress is modified by dietary fat: evidence from a human intervention study. Clin Sci (Lond) 2010; 119: 251-61.
142. Warensjö E, Risérus E, Vessby B. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia 2005; 48: 1999-2005.
143. Laaksonen DE, Lakka TE, Lakka HM, et al. Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabetes Med 2002; 19: 456-64.
144. Calder PC. Polyunsaturated fatty acids and inflammation. Biochem Soc Trans. 2005; 33: 423-7.
145. Magrone T, Jirillo E. Potential application of dietary polyphenols from red wine to attaining healthy ageing. Curr Top Med Chem 2011; 11: 1780-96.
146. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992: 339: 1523-6.
147. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction: to die or not to die. Mol Nutr Food Res 2009; 53: 115-28.
148. Sato M, Suzuki Y, Okuda T, Yokotsuka K. Contents of resveratrol, piceid, and their isomers in commercially available wines made from grapes cultivated in Japan. Biosci Biotechnol Biochem 1997; 61: 1800-5.
149. Dugo G, Salvo F, Dugo P, La Torre GL, Mondello L. Antioxidants in Sicilian wines: analytic and compositive aspects. Drugs Exp Clin Res 2003; 29: 189-202.
150. Saiko P, Szakmary A, Jaeger W, et al. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 2008: 68-94.
151. Zhu J, Yong W, Wu X, et al. Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun 2008; 369: 471-7.
152. Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009; 77: 1053-63.
153. Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009; 207: 420-7.
154. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004; 279: 22727-37.
155. Wang S, Qian Y, Gong D, Zhang Y, Fan Y. Resveratrol attenuates acute hypoxic injury in cardiomyocytes: correlation with inhibition of iNOS-NO signaling pathway. Eur J Pharm Sci 2011; 44: 416-21.
156. Crandall JP, Oram V, Trandafirescu G, et al. Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance. Gerontol A Biol Sci Med Sci. 2012 Epub ahead of print.
157. Chiva-Blanch G, Urpi-Sarda M, Llorach R, et al. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial. Am J Clin Nutr 2012; 95: 326-34.
158. Fletcher RJ. Food sources of phyto-oestrogens and their precursors in Europe. Br J Nutr 2003; 89 (Suppl 1): S39-43.
159. Jackman KA, Woodman OL, Sobey CG. Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights. Curr Med Chem 2007; 14: 2824-30.
160. Yamori Y. Food factors for atherosclerosis prevention: Asian perspective derived from analyses of worldwide dietary biomarkers. Exp Clin Cardiol 2006; 11: 94-8.
161. Bitto A, Altavilla D, Bonaiuto A, et al. Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome. J Endocrinol 2009; 200: 367-76.
162. Lukaczer D, Liska DJ, Lerman RH, et al. Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. Nutrition 2006; 22: 104-13.
163. Simão AN, Lozovoy MA, Simão TN, Dichi JB, Matsuo T, Dichi I. Nitric oxide enhancement and blood pressure decrease in patients with metabolic syndrome using soy protein or fish oil. Arq Bras Endocrinol Metabol 2010; 54: 540-5.
164. Bahls LD, Venturini D, Scripes Nde A, et al. Evaluation of the intake of a low daily amount of soybeans in oxidative stress, lipid and inflammatory profile, and insulin resistance in patients with metabolic syndrome. Arq Bras Endocrinol Metabol 2011; 55: 399-405.
165. Azadbakht L, Kimiagar M, Mehrabi Y, Esmaillzadeh A, Hu FB, Willett WC. Soy consumption, markers of inflammation, and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. Diabetes Care 2007; 30: 967-73.
166. Huang Y, Cao S, Nagamani M, Anderson KE, Grady JJ, Lu LJ. Decreased circulating levels of tumor necrosis factor-alpha in postmenopausal women during consumption of soy-containing isoflavones. J Clin Endocrinol Metab 2005; 90: 3956-62.
167. Alappat L, Awad AB. Curcumin and obesity: evidence and mechanisms. Nutr Rev 2010; 68: 729-38.
168. Jang EM, Choi MS, Jung UJ, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fatfed hamsters. Metabolism 2008; 57: 1576-83.
169. Khan N, Monagas M, Andres-Lacueva C, et al. Regular consumption of cocoa powder with milk increases HDL cholesterol and reduces oxidized LDL levels in subjects at high-risk of cardiovascular disease. Nutr Metab Cardiovasc Dis 2011 [Epub ahead of print].
170. Vázquez-Agell M, Urpi-Sarda M, Sacanella E, et al. Cocoa consumption reduces NF-+B activation in peripheral blood mononuclear cells in humans. Nutr Metab Cardiovasc Dis 2011 Aug 6. [Epub ahead of print].
171. Vallverdú-Queralt A, Medina-Remón A, Martínez-Huélamo M, Jáuregui O, Andres-Lacueva C, Lamuela-Raventos RM. Phenolic profile and hydrophilic antioxidant capacity as chemotaxonomic markers of tomato varieties. J Agric Food Chem 2011; 59: 3994-4001.
172. Stewart AJ, Bozzonet S, Mullen W, Jenkins GI, Lean ME, Crozier A. Occurrence of flavonols in tomatoes and tomato-based products. J Agric Food Chem 2000; 48: 2663-9.
173. Giovanucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med (Maywood) 2002; 227: 852-9.
174. Tinahones FJ, Rubio MA, Garrido-Sánchez L, et al. Green tea reduces LDL oxidability and improves vascular function. J Am Coll Nutr 2008; 27: 209-13.
175. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 2008; 138: 1677-83.
176. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348: 2599-608.
177. Giugliano D, Esposito K. Mediterranean diet and metabolic diseases. Curr Opin Lipidol 2008; 19: 63-8.
178. Márquez-Sandoval F, Bulló M, Vizmanos B, Casas-Agustench P, Salas Salvadó J. Un patrón de alimentación saludable: la dieta Mediterránea tradicional. Antropo 2008; 16: 11-22.
179. Weinbrenner T, Fitó M, de la Torre R, et al. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. J Nutr 2004; 134: 2314-21.
180. Lopez-Miranda J, Gómez P, Castro P, et al. Mediterranean diet improves low density lipoprotein susceptibility to oxidative modifications. Med Clin (Barc) 2000; 115: 361-5.
181. Galli C, Visioli F. Antioxidant properties of Mediterranean diet. Int J Vitam Nutr Res 2001; 171: 185-8.
182. Ruano J, López-Miranda J, Fuentes J, et al. Phenolic content of olive virgin oil improves ischemic reactive hyperemia in hypercholesterolemic patients. J Am Coll Cardiol 2005; 46: 1864-68.
183. Pérez-Martínez P, García-Ríos A, Delgado-Lista J, Pérez-Jiménez F, López-Miranda J. Mediterranean diet rich in olive oil and obesity, metabolic syndrome and diabetes mellitus. Curr Pharm Des 2011: 17: 769-77.
184. Soriguer F, Almaraz MC, Ruiz-de-Adana MS, et al. Incidence of obesity is lower in persons who consume olive oil. Eur J Clin Nutr 2009; 63: 1371-4.
185. Kontogianni MD, Panagiotakos DB, Chrysohoou C, Pitsavos C, Zampelas A, Stefanadis C. The impact of olive oil consumption pattern on the risk of acute coronary syndromes: The CARDIO2000 case-control study. Clin Cardiol 2007; 30: 125-9.
186. Tierney AC, Roche HM. The potential role of olive oil-derived MUFA in insulin sensitivity. Mol Nutr Food Res 2007; 51: 1235-48.
187. Keys A, Menotti A, Karvonen MJ, et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol 1986; 124: 903-15.
188. Pérez-Jiménez F, Castro P, López-Miranda J, et al. Circulating levels of endothelial function are modulated by dietary monounsaturated fat. Atherosclerosis 1999; 145: 351-8.
189. Jones JL, Comperatore M, Barona J, et al. A Mediterranean-style, low-glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome. Metabolism. Epub ahead of print 2011.
190. Marin C, Delgado-Lista J, Ramirez R, et al. Mediterranean diet reduces senescence-associated stress in endothelial cells. Age (Dordr). Epub ahead of print 2011.
191. Yubero-Serrano EM, González-Guardia L, Rangel-Zuñiga O, et al. Mediterranean Diet Supplemented With Coenzyme Q10 Modifies the Expression of Proinflammatory and Endoplasmic Reticulum Stress-Related Genes in Elderly Men and Women. J Gerontol A Biol Sci Med 2012; 67: 3-10.
192. Salas-Salvadó J, García-Arellano A, Estruch R, et al. Components of the Mediterranean-type food pattern and serum inflammatory markers among patients at high risk for cardiovascular disease. Eur J Clin Nutr 2008; 62: 651-9.
193. Perez-Martinez P, López-Miranda J, Blanco-Colio L, et al. The chronic intake of a Mediterranean diet enriched in virgin olive oil, decreases nuclear transcription factor kappaB activation in peripheral blood mononuclear cells from healthy men. Atherosclerosis 2007; 194: 141-6.
194. De Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alphalinolenic acid-rich in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-9.
195. Estruch R, Martínez-González MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006; 145: 1-11.
196. Estruch R. Anti-inflammatory effects of the Mediterranean diet: the experience of the PREDIMED study. Proc Nutr Soc 2010; 69: 333-40.
197. Salas-Salvadó J, Bulló M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011; 34: 14-9.
198. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534, 906 individuals. J Am Coll Cardiol 2011; 57: 1299-313.